Matches children and young people to leukemia treatment plans
Part of Blood & lymphatic, Cancer clinical trials.
This trial is set up to review tumor lab test results to help doctors choose the most appropriate next treatment for people with leukemia that has returned or did not respond. It mainly matters for younger patients who are not already on a standard treatment path.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have leukemia or another blood cancer that is back or not responding
- You were diagnosed before age 18, and you are under 25 when you join the study
- You are being treated in a pediatric or young adult (AYA) cancer program, with no current standard treatment plan
- Your expected lifetime is at least 6 weeks
- Your tumor has had molecular testing, and the results are available
- Your tumor has had flow cytometry testing in a certified lab, and the results are available
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
This trial studies different treatment plans for children and teens newly diagnosed with AML (a type of blood cancer). Depending on the child's tumor markers and risk group, they may be offered an extra drug (quizartinib) or a targeted antibody (Mylotarg) to see if it improves outcomes.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial tests an experimental immunotherapy (PA3-17) designed to target and kill cancer cells that carry the CD7 marker in children and teens with T-cell leukemia or lymphoma that has returned or is hard to treat. It aims to see if the treatment is safe and effective at the best dose.
This trial tests an experimental treatment called BG1805 for children with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. BG1805 is a type of cell therapy (like CAR-T) that targets the CLL-1 marker on leukemia cells, potentially helping the body fight the cancer.
Hear when a new Relapsed Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.